How does XNCR's PS Ratio compare to its peers?

XNCR is expensive based on its Price-To-Sales Ratio (20.6x) compared to the peer average (18.7x).

How does XNCR's PS Ratio compare vs other companies in the US Biotechs Industry?

XNCR is expensive based on its Price-To-Sales Ratio (20.6x) compared to the US Biotechs industry average (9.7x).

What is XNCR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XNCR is expensive based on its Price-To-Sales Ratio (20.6x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

What is the Fair Price of XNCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

XNCR ($25.01) is trading above our estimate of [[fair value]] ($17.07)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Xencor (Nasdaq:XNCR) - Stock Price, News & Analysis

XNCR Stock Overview

A clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. More details

XNCR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 29.46% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Xencor, Inc. Competitors

Dynavax Technologies

NasdaqGS:DVAX

US$1.6b

NewAmsterdam Pharma

NasdaqGM:NAMS

US$1.9b

Arcus Biosciences

NYSE:RCUS

US$1.3b

Travere Therapeutics

NasdaqGM:TVTX

US$1.6b

Price History & Performance

Summary of all time highs, changes and price drops for Xencor
Historical stock prices
Current Share Price	US$25.01
52 Week High	US$26.84
52 Week Low	US$15.31
Beta	0.66
11 Month Change	18.19%
3 Month Change	42.10%
1 Year Change	33.46%
33 Year Change	-29.43%
5 Year Change	-36.52%
Change since IPO	199.88%

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Sep 12

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Sep 12

Recent updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Shareholder Returns

	XNCR	US Biotechs	US Market
7D	8.4%	2.5%	2.2%
1Y	33.5%	16.1%	31.6%

Return vs Industry: XNCR exceeded the US Biotechs industry which returned 16.2% over the past year.

Return vs Market: XNCR exceeded the US Market which returned 31.7% over the past year.

Price Volatility

Is XNCR's price volatile compared to industry and market?
XNCR volatility
XNCR Average Weekly Movement	8.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: XNCR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: XNCR's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	280	Bassil Dahiyat	www.xencor.com

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.

Xencor, Inc. Fundamentals Summary

How do Xencor's earnings and revenue compare to its market cap?
XNCR fundamental statistics
Market cap	US$1.75b
Earnings (TTM)	-US$198.24m
Revenue (TTM)	US$85.16m

20.6x

P/S Ratio

-8.8x

P/E Ratio

Is XNCR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XNCR income statement (TTM)
Revenue	US$85.16m
Cost of Revenue	US$239.68m
Gross Profit	-US$154.51m
Other Expenses	US$43.73m
Earnings	-US$198.24m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.83
Gross Margin	-181.43%
Net Profit Margin	-232.77%
Debt/Equity Ratio	2.5%

How did XNCR perform over the long term?

See historical performance and comparison

XNCR Stock Overview

Rewards

Risk Analysis

Xencor, Inc. Competitors

NasdaqGS:DVAX

US$1.6b

NasdaqGM:NAMS

US$1.9b

NYSE:RCUS

US$1.3b

NasdaqGM:TVTX

US$1.6b

Price History & Performance

Recent News & Updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Recent updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Xencor, Inc. has filed a Follow-on Equity Offering.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors